J&J: Janssen unit submits prostate cancer drug application
(CercleFinance.com) - Janssen, the pharmaceutical unit of US healthcare giant Johnson & Johnson, said on Friday that it has filed a marketing application to European regulators for the use of its experimental drug apalutamide to treat patients with prostate cancer.
The submission is based on a Phase 3 clinical trial that showed a 72% reduction in the risk of distant metastasis or death compared to placebo in patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
Apalutamide is an oral androgen receptor (AR) inhibitor that blocks the androgen signaling pathway in prostate cancer cells.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The submission is based on a Phase 3 clinical trial that showed a 72% reduction in the risk of distant metastasis or death compared to placebo in patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
Apalutamide is an oral androgen receptor (AR) inhibitor that blocks the androgen signaling pathway in prostate cancer cells.
Copyright (c) 2018 CercleFinance.com. All rights reserved.